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Abstract
Background: Matrix metalloproteinase-9 (MMP-9) may be important in the progression of emphysema, but there
have been few longitudinal clinical studies of MMP-9 including pulmonary status and COPD exacerbation
outcomes.
Methods: We utilized data from the placebo arm (n = 126) of a clinical trial of patients with alpha1-antitrypsin
deficiency (AATD) and emphysema to examine the links between plasma MMP-9 levels, pulmonary status, and
COPD exacerbations over a one year observation period. Pulmonary function, computed tomography lung density,
incremental shuttle walk test (ISWT), and COPD exacerbations were assessed at regular intervals over 12 months.
Prospective analyses used generalized estimating equations to incorporate repeated longitudinal measurements of
MMP-9 and all endpoints, controlling for age, gender, race-ethnicity, leukocyte count, and tobacco history.
A secondary analysis also incorporated highly-sensitive C-reactive protein levels in predictive models.
Results: At baseline, higher plasma MMP-9 levels were cross-sectionally associated with lower FEV1 (p = 0.03), FVC
(p < 0.001), carbon monoxide transfer factor (p = 0.03), resting oxygen saturation (p = 0.02), and ISWT distance
walked (p = 0.02) but were not associated with radiographic lung density or total lung capacity (TLC). In
longitudinal analyses, MMP-9 predicted a further decline in transfer factor (p = 0.04) and oxygen saturation (p <
0.001). MMP-9 also predicted worsening lung density (p = 0.003), increasing TLC (p = 0.02), and more frequent
COPD exacerbations over follow-up (p = 0.003). Controlling additionally for hs-CRP levels did not substantively
change the longitudinal associations between MMP-9 and these outcomes.
Conclusions: Increased plasma MMP-9 levels generally predicted pulmonary status declines, including worsening
transfer factor and lung density as well as greater COPD exacerbations in AATD-associated emphysema.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide, but
predictors of progression remain elusive [1]. Alpha1-
antitrypsin inhibits neurophil elastase, and the discovery
of alpha1-antitrypsin deficiency (AATD) and its associa-
tion with emphysema and COPD helped to establish the
concept that an imbalance between proteases and anti-
proteases, exacerbated by exposure to cigarette smoke,
can play a key role in the development of disease, at
least in a subset of COPD [2]. Evolving evidence sug-
gests that a variety of proteinases, acting on diverse sub-
strates of the extracellular matrix, play an important
role in pulmonary parenchymal destruction in COPD
[3,4]. The study of these proteinases has been compli-
cated by the diversity of COPD phenotypes, which
include components of emphysema and chronic bron-
chitis, as well as the common co-morbid cardiovascular
and other systemic diseases associated with COPD, all
of which potentially confound the analyses of biomar-
ker-disease associations [1,5]. Because AATD-associated
emphysema represents a more homogenous phenotype
of COPD, with a more rapid decline in pulmonary sta-
tus, generally at a younger age with fewer comorbidities,
it offers a potential modelf o ru n d e r s t a n d i n gC O P D
pathogenesis with respect to proteinases beyond those
directly inhibited by alpha1-antitrypsin [2,6].
Matrix metalloproteinase-9 (MMP-9) is one such pro-
teinase that has received considerable attention in
COPD [7-18]. Clinical studies have suggested that,
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with lung disease, MMP-9 may be particularly impor-
tant, although there have been few longitudinal studies
of MMP-9 and few pulmonary status outcomes exam-
ined [7-10]. Of the 143 serologic biomarkers examined
by Pinto-Plata and colleagues, MMP-9 was the most
highly correlated with the BODE Index (cross-section-
ally) and with COPD exacerbations (longitudinally over
12 months) [7]. Additionally, the ratio of biomarker in
COPD subjects to that in health controls was higher for
MMP-9 than for any of the other biomarkers examined
[7]. Higashimoto and colleagues examined multiple bio-
markers among 96 COPD patients, finding that only
MMP-9 and C-reactive protein were statistically signifi-
cantly associated with declines in FEV1 over the follow-
ing 12 months [8]. Neither these nor other longitudinal
studies of MMP-9 have investigated pulmonary status
measured by transfer factor for carbon monoxide
(TLco), radiographically-quantified lung density, or exer-
cise capacity. Studies to date have furthermore not
incorporated multiple longitudinal measurements of
MMP-9. Finally, clinical studies thus far have not
reported on the longitudinal associations between
MMP-9 and outcomes within the context of AATD-
associated emphysema, a phenotype of COPD that
could be particularly relevant to understanding the role
of MMP-9 in the natural history of COPD pathogenesis.
Utilizing data from the placebo arm of a clinical trial,
we tested the hypotheses that plasma MMP-9 levels are
cross-sectionally and prospectively associated with pul-
monary status declines and with COPD exacerbations
among emphysema patients with AATD.
Methods
Overview
We analyzed data from the placebo arm of the Retinoids
in Emphysema Patients on Alpha1-Anitrypsin Interna-
tional Registry (REPAIR) trial, which has previously
been described in detail [19]. This was a randomized
double-blind trial that investigated the potential for a
retinoid agonist to slow the progression of emphysema
in AATD patients. Using measurements collected as
part of this clinical trial, we investigated the cross-
sectional and longitudinal association between plasma
MMP-9 and multiple pulmonary endpoints, including
COPD exacerbation frequency. For example, in longitu-
dinal analyses, our goal was to determine the anticipated
change in pulmonary status that would be predicted by
higher levels of plasma MMP-9 in a given individual
represented by this cohort.
Participants
For the REPAIR trial, Pi Z and Pi Null genotype subjects
with emphysema were recruited from 10 alpha1-
antitrypsin registries in 10 countries. 126 subjects with
AATD-associated emphysema were randomized to the
placebo arm of the trial and provided plasma samples
sufficient for analysis of MMP-9. Inclusion criteria and
exclusion have previously been described [19]. Notable
inclusion criteria were: (1) no alpha1-antitrypsin aug-
mentation therapy for at least 28 days prior to enrol-
ment, (2) TLco < 70% and a post-bronchodilator FEV1
≤ 80% of the predicted values for sex, age, and height;
(3) no use of systemic corticosteroids within 28 days
prior to enrolment; and (4) ability to perform an incre-
mental shuttle walk test (ISWT) without supplemental
oxygen. Subjects were excluded if (1) they had experi-
enced >3 COPD exacerbations in the year prior to
enrolment or (2) were current tobacco smokers or had
smoked tobacco in the 6 months prior to enrolment.
The REPAIR trial was approved by relevant local ethics
review committees and was conducted in accordance
with the Declaration of Helsinki and Good Clinical
Practice guidelines. All patients provided written
informed consent.
Biomarker Analysis
We focused our analysis on MMP-9 because of ap r i o r i
evidence of its importance in COPD [7-12,20], although
various biomarkers were measured as part of the
REPAIR trial. As a secondary analysis, however, we also
included plasma levels of highly-sensitive C-reactive pro-
tein (hs-CRP) in longitudinal multivariable analyses.
For protein biomarker analyses, venous whole blood
samples were collected into standard vacutainer tubes
containing EDTA as an anticoagulant. After centrifuga-
tion for 10 minutes at 1,800 × g at 4°C, samples were
kept frozen at -70°C until measurement. All samples for
any given subject over the study period were run simul-
taneously after the subject completed the 52 week trial
period. Plasma MMP-9 and hs-CRP levels were quanti-
fied at baseline, 3 months and 6 month by Pathway
Diagnostics (Malibu, CA). MMP-9 was analyzed using
Searchlight
® MMP-9 assays (Pierce, Rockford, IL). This
assay consists of sandwich enzyme-linked immunosor-
bent assay for the quantitative measurement of total
MMP-9 (the combination of pro-form and active form
MMP-9). The enzyme-substrate reaction produces a
chemiluminescent signal detected with a cooled Charge-
Coupled Device camera (Pierce). The representative
sample range for this MMP-9 assay, obtained from
duplicate analysis of 20 human subjects without known
history of active disease, is 4.2 ng/ml to 120 ng/ml.
Although serum has sometimes been used in the analy-
sis of MMP-9 [7-9], analysis of plasma MMP-9 has been
shown to provide superior accuracy [21]. Plasma hs-
CRP levels were determined by use of the Immulite
®
High Sensitivity CRP test kit (Siemens Healthcare
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CRP quantification, each sample was assayed twice and
the mean value of the two measurements was used. The
mean intra-assay coefficient of variation (CV) was <15%
for both assays. As a covariate in all multivariable ana-
lyses, we also included leukocyte count since this could
be related to MMP-9 levels; leukocyte count was avail-
able from standard complete blood count (CBC) ana-
lyzed in a central laboratory.
Baseline biomarker results were used for cross-
sectional analyses. For longitudinal analyses, we exam-
ined the predictive association of biomarker results from
the baseline, 3 month, and 6 month time-points with
the frequency of subsequent COPD exacerbations and
subsequent changes in pulmonary status (lung function,
exercise capacity and radiographic lung density). As dis-
cussed below, the schedule of assessments for different
pulmonary status measures varied in the REPAIR trial,
necessitating different modeling time periods in longitu-
dinal repeated measures analyses (Figure 1).
Study Endpoints
1. Pulmonary Function Testing (PFT)
PFT measurements, including TLco, post-bronchodilator
FEV1 and forced vital capacity (FVC), and total lung
capacity (TLC) were assessed at baseline, 3 months,
6 months, and 9 months, according to European
Respiratory Society (ERS) guidelines [22,23]. Based
on spirometry results, patients were staged by Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria [24]. TLC was measured by body box plethys-
mography when possible, but helium dilution was used
at study sites that did not have access to a body plethys-
mograph or if subjects were unable to perform box
p l e t h y s m o g r a p h y( 2 5 %o fs u b j e c t si nt h i sa n a l y s i sh a d
TLC measured by helium dilution). The study protocol
required that the same method for assessing TLC had
to be used with each subject in longitudinal follow-up.
MMP-9 levels were not statistically significantly different
between sites that used body plethysmograph and
helium dilution techniques at baseline, 3 months, or
6 months (p-values for difference, based on Wilcoxon
rank-sum test were 0.24, 0.52, and 0.94 respectively).
We assessed the cross-sectional baseline correlation of
plasma MMP-9 with FEV1,F V C ,F E V 1/FVC ratio, TLC,
and TLco (unadjusted for lung volume or hemoglobin).
We furthermore determined the prospective association
of (1) MMP-9 at baseline with the changes in PFT mea-
surements (FEV1, FVC, FEV1/FVC ratio, TLC and TLco)
between baseline and 3 months, (2) MMP-9 at 3 months
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Figure 1 Timeline of repeated measures models for longitudinal analyses. Several repeated measures models were used to assess the
longitudinal association of MMP-9 with the number (#) of subsequent COPD exacerbations or the subsequent changes (Δ) in various pulmonary
status measures. The schedule of assessments for different pulmonary status measures varied in the REPAIR trial, necessitating different modeling
time periods.
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3m o n t h sa n d6m o n t h s ,a n d( 3 )M M P - 9a t6m o n t h s
with PFT changes between 6 months and 9 months.
2. Exercise Testing and Oxygen Saturation
Incremental shuttle walk tests (ISWT) were performed
at baseline, 6 months, and 12 months using standard
protocols [25]. The primary outcome measure for the
ISWT is total distance walked. Resting room air oxygen
saturation by pulse oximetry was obtained prior to
ISWT and used separately for analysis. The baseline cor-
relations of MMP-9 with both ISWT distance and rest-
ing oxygen saturation were determined. We furthermore
determined the prospective association between (1) base-
l i n eM M P - 9a n db o t hc h a n g ei nI S W Td i s t a n c ea n d
change in oxygen saturation between baseline and
6 months, and (2) MMP-9 at 6 months with change in
ISWT distance and oxygen saturation between 6 months
and 12 months.
3. Computed Tomography (CT) Lung Densitometry
The proteolytic tissue destruction that is pathognomonic
of emphysema should directly cause a reduction of lung
density. Lung density changes can be measured using
CT scanning, and CT lung densitometry is thought to
be the most sensitive and specific measure of emphy-
sema in vivo [26-31]. Specifically, CT scanning has been
validated as a measure of emphysema by studies that
have shown good correlation with pathology [32,33],
exercise capacity [34], health status [34] and lung func-
tion [30,35]. Furthermore, CT densitometry is a better
predictor of mortality than lung function in AATD-
associated emphysema [36]. For this reason, change in
CT-measured lung density was chosen as the primary
end-point to examine the efficacy of the study drug in
the REPAIR trial [19].
CT scans were performed at baseline, 6 months, and
12 months. For the purposes of volume adjustment, two
CT scans were performed at each visit, one scan during
a breath-hold at TLC followed immediately by a second
scan at approximately functional residual capacity (FRC)
[37]. Lung density was assessed as the value in Houns-
field Units (HU) at which 15% of the lung voxels have a
lower density (15
th percentile method) [26]. We assessed
both the cross-sectional baseline correlation of MMP-9
with volume-adjusted lung density as well as the pro-
spective association of MMP-9 with changes in volume-
adjusted lung density. Specifically, for prospective ana-
lyses, we determined (1) the association of MMP-9 at
baseline with the change in lung density between base-
line and 6 months and (2) the association of MMP-9 at
6 months with the change in lung density between 6
months and 12 months.
4. Acute Exacerbations of COPD
Patients in the REPAIR trail were seen in clinic at least
every 4 weeks (more often if they developed new
complaints) to assess for adverse events. As part of
this ascertainment, any new prescriptions for antibio-
tics or systemic corticosteroids for respiratory reasons
were recorded, along with the dates of administration.
Following precedent and the recommendation of work-
ing groups and disease experts, a COPD exacerbation
was defined as a prescription of systemic corticoster-
oids or antibiotics for worsening respiratory status
[38-40]. As advocated by Burge and Wedzicha, we
classified various prescriptions as a single episode
when the interval between adjacent contacts was
<14 days [38].
Statistical Analysis
Primary Analyses
Statistical analysis used Stata/SE software (version 9.2,
College Station, TX). This wasa ne x p l o r a t o r yp o s t - h o c
analysis, and because of the risk of Type II error, we
did not adjust for multiple comparisons resulting from
either the multiple outcomes examined or the fact that
other data were potentially available for analyses [41].
Our a priori hypotheses focused on the potential asso-
ciations of MMP-9 with COPD progression and
outcomes.
All multivariable analyses of MMP-9 controlled for
age, gender, race-ethnicity, leukocyte count, and tobacco
pack-year history. Each of these factors was considered
to be a potential confounder in the relationship between
MMP-9 levels and poor outcomes. For example, leuko-
cytes may release MMP-9 and, potentially, could inde-
pendently be a predictor of future COPD exacerbations.
Therefore, leukocyte count obtained simultaneous to the
point in time of MMP-9 measurements was included as
a covariate in cross-sectional and longitudinal analyses.
In our analysis of TLC, we also controlled for method
of TLC assessment (body box plethysmography vs.
helium dilution).
Baseline cross-sectional associations of MMP-9 with
study end-points were assessed using multivariable
linear regression, with the aforementioned study end-
points as the dependent variable and MMP-9 and cov-
ariates as independent variables.
Because prospective analyses involved multiple assess-
ments of MMP-9 and outcomes for each subject over
time, we used a repeated measures analysis that incor-
porated all periods of follow-up data simultaneously.
Specifically, we used generalized estimating equations to
take into account the fact that a given subject contribu-
ted more than one observation to the analysis [42-45].
All outcomes other than COPD exacerbations were
modelled as changes in a measurement from one period
to the next, and such changes were well-approximated
by a normal distribution, which was incorporated into
our modelling.
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of COPD exacerbations within each of the 3 month
observation periods followed a Poisson distribution, and
our generalized estimating equations thus incorporated
such a distribution to model not simply the presence or
absence of a COPD exacerbation but the number of
exacerbations in any given 3 month time-frame.
As a descriptive analysis, we also evaluated (1) the
longitudinal change in MMP-9 levels as well as (2) the
change in each outcome measure over the study period
irrespective of MMP-9 levels. We examined the latter to
gauge the magnitude of the overall changes in each
measurement, to better place into context the changes
associated with MMP-9 levels. We used the paired t-test
to examine whether these changes were different than
zero. For pulmonary function measurements, which
were done every 3 months over a 9 month period, we
presented the overall change as an annualized rate to
make it comparable to the other measurements.
Secondary Analyses
C-reactive protein (CRP) has been studied extensively in
COPD and has been shown to predict declines in lung
function as well as COPD outcomes, such as risk of hos-
pitalization and death from COPD [46,47]. CRP is an
acute-phase reactant and is associated with systemic as
well as lung inflammation in COPD [46]. As such,
whether or not MMP-9 may predict COPD progression
or outcomes after controlling for CRP levels may be of
interest both to (1) those wishing to understand whether
MMP-9 may add incremental predictive value above and
beyond CRP as well as (2) those wishing to know if any
associations between MMP-9 and pulmonary outcomes
persist after controlling for non-specific inflammation
using a well-validated measure. In this analysis, there-
fore, we controlled additionally for hs-CRP levels in our
multivariable models. Furthermore, we utilized the
Spearman rank test to examine correlations between hs-
CRP and MMP-9 levels at baseline, 3 months, and
6 months.
To provide insight into whether MMP-9 might add
incremental predictive value above and beyond degree
of disease severity, we conducted a secondary analysis,
based on our longitudinal multivariable models, in
which we controlled for either FEV1 or FEV1/FVC ratio
in addition to the covariates used in our core analyses
(age, gender, race-ethnicity, leukocyte count, and
tobacco pack-year history). For this analysis, we utilized
FEV1 and FEV1/FVC ratio results that were obtained
simultaneous to the point in time at which MMP-9 was
measured (i.e., at the beginning of each longitudinal per-
iod of follow-up).
Because a COPD exacerbation may theoretically affect
the level of plasma MMP-9 and independently be asso-
ciated with subsequent COPD exacerbations, we
performed another secondary analysis in which we con-
trolled for prior COPD exacerbations. For example, in
this secondary analysis, the modelling of COPD exacer-
bations between 3 and 6 months controlled for whether
subjects had had a COPD exacerbation between baseline
and 3 months. This analysis was not able to control for
the presence or absence of COPD exacerbations prior to
baseline because such data were not available, although
by exclusion criteria patients could not have been trea-
ted with systemic corticosteroids in the 28 days prior to
baseline nor had >3 exacerbations in the year prior to
enrolment.
Results
Subject Characteristics
The mean subject age at baseline was 53.8 (SD =
8.5 years), 27% of subjects were female, and all subjects
w e r eC a u c a s i a n( T a b l e1 ) .T h ev a s tm a j o r i t yo fs u b j e c t s
(89%) had a tobacco smoking history, with an average
Table 1 Baseline characteristics of 126 subjects with
AATD-associated emphysema
Mean ± SD or N (%)
Age, years 53.8 ± 8.5
Female 34 (27%)
Caucasian race 126 (100%)
Tobacco Status
Never Smoker 14 (11%)
Former Smoker* 112 (89%)
Pack-Years (among former smokers) 19.0 ± 12.4
Body-Mass Index 25.2 ± 4.3
FEV1,% predicted 46.5% ± 16.8%
FEV1/FVC 0.38 ± 0.11
Total Lung Capacity, % predicted 149% ± 45%
GOLD Stage
1 21 (17%)
2 56 (44%)
3 47 (37%)
4 2 (2%)
Transfer Factor (TLco), mmol/min/kpa 4.9 ± 1.6
Transfer Factor, % predicted 48% ± 15%
CT Densitometry
Adjusted Lung Density
† -956.2 ± 16.0
Resting Oxygen Saturation (room air) 93.5% ± 2.8%
Incremental Shuttle Walk Test
Distance Walked, meters 406 ± 203
MMP-9 level (ng mL
-1)
Median (25
th to 75
th Interquartile Range) 28.3 (17.8 - 55.4)
*5 subjects (4%) had quit smoking 6-12 months prior to baseline. The
remainder of former smokers had quit smoking >12 months prior to baseline.
There were no current smokers by study exclusion criteria.
†Measured in Hounsfield Units at the 15
th percentile.
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Per study exclusion criteria, there were no known cur-
rent smokers or recent ex-smokers in the group. The
mean FEV1 % predicted was 46.5% (SD = 16.8%), and
the mean FEV1/FVC ratio was 0.38 (SD = 0.11). Addi-
tional baseline subject characteristics are shown in
Table 1.
Baseline Association of MMP-9 with Pulmonary Status
After controlling for sociodemographic factors, tobacco
history, and leukocyte count, MMP-9 at baseline was
associated with multiple deficits in pulmonary status (all
changes stated per 25
th-75
th percentile interquartile
range [IQR) increment in MMP-9). As shown in Table 2,
these deficits were: lower FEV1 (-32 ml; 95% confidence
interval [CI] -61 to -4; p = 0.03), lower FVC (-105 ml;
95% CI -160 to -52; p < 0.001), lower TLco (-0.1 mmol/
min/kpa; 95% CI -0.2 to -0.01; p = 0.03), lower resting
oxygen saturation (-0.2%; 95% CI -0.3% to -0.03%; p =
0.02), and less distance walked on the ISWT (-12 meters;
95% CI -22 to -2; p = 0.02). MMP-9 was not statistically
associated at baseline with lung density, FEV1/FVC ratio,
or TLC (Table 2).
Longitudinal Changes in Pulmonary Status and MMP-9
Between baseline and 6 months, MMP-9 declined on
average by 13.2 ng/ml (95% CI -33.6 to +7.1; p = 0.20);
changes in MMP-9 by subject are presented in Figure 2.
Without taking into account MMP-9 levels, we evalu-
ated the change in pulmonary status measurements over
the study period and present these results on an
annualized (12 month) basis. TLco declined on average
by 0.2 mmol/min/kpa (95% CI -0.34 to -0.08; p = 0.002)
while lung density declined on average by 1.8 HU (95%
CI -2.4 to -1.1; p < 0.001). FEV1 declined by 36 ml (95%
CI -67 to -5; p = 0.025) and FEV1/FVC ratio declined by
1% (95% CI -2% to -0.02%; p = 0.046). The changes in
other outcome measurements were not statistically sig-
nificant (Table 3).
As shown in Table 4, an interquartile range higher
level of MMP-9 predicted a 0.1 mmol/min/kpa annual
Table 2 Baseline cross-sectional association of plasma
MMP-9 with pulmonary status among 126 alpha1-
antitrypsin deficient subjects with emphysema
Δ (95% CI)* P-value
Spirometry
FEV1, ml -32 (-61 to -4) 0.03
FVC, ml -105 (-160 to -52) <0.001
FEV1/FVC ratio +0.2% (-0.3% to +0.7%) 0.47
Total Lung Capacity, ml -64 (-154 to +26) 0.16
Transfer Factor (TLco), mmol/min/kpa -0.1 (-0.2 to -0.01) 0.03
CT densitometry
Adjusted Lung Density
† -0.24 (-1.1 to +0.6) 0.58
Resting O2 saturation (room air) -0.2% (-0.3% to -0.03%) 0.02
Incremental Shuttle Walk Test
Distance Walked, meters -12 (-22 to -2) 0.02
All analyses controlled for age, gender, race-ethnicity, leukocyte count, and
tobacco pack-year history. Analysis of total lung capacity also controlled for
method of lung capacity assessment (box plethysmography vs helium
dilution).
*Change (Δ) associated cross-sectionally with a 25
th -7 5
th percentile
interquartile range higher level of MMP-9.
†Measured in Hounsfield Units at the 15
th percentile.
0%
10%
20%
30%
40%
% of 
Subjects
with
Change
<-150 -100 0 100 150 -50 50
ng/ml
Figure 2 Change in MMP-9 levels by subject from baseline to
6 months.
Table 3 Change in pulmonary status measurements over
the entire study period
Annualized change in
measurements
over study period
Mean (95% CI)* P-
value*
Spirometry
†
FEV1, ml -36 (-67 to -5) 0.025
FVC, ml -6 (-113 to +102) 0.92
FEV1/FVC ratio -1% (-2% to -0.02%) 0.046
Total Lung Capacity, ml
† -48 (-152 to +56) 0.36
Transfer Factor (TLco), mmol/min/kpa
† -0.2 (-0.34 to -0.08) 0.002
CT Densitometry
Adjusted Lung Density
‡ -1.8 (-2.4 to -1.1) <0.001
Resting Oxygenation Saturation (room
air)
0.2% (-0.3% to
+0.6%)
0.43
Incremental Shuttle Walk Test
Distance Walked, meters -8 (-23 to +6) 0.26
*95% confidence interval (CI) and P-value were calculated using the paired
t-test, which determined the 95% CI of the observed changes in each
measurement over the study period and tested whether these changes were
different than 0.
†Change in pulmonary function testing (PFT) measurements, which for the
purposes of this study were measured over a 9 month period, are presented
after extrapolation to an annualized (12 month) basis.
‡Measured in Hounsfield Units at the 15
th percentile.
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HU annual decline in radiographic lung density (95% CI
-1.1 to -0.2; p = 0.003), and a 0.5% absolute annual
decline in oxygen saturation (95% CI -0.7% to -0.3%; p <
0.001). MMP-9 was not statistically associated with a fall
in the distance walked on the ISWT (-6 meters; 95% CI
-15 to +2; p = 0.16). Higher levels of MMP-9 were asso-
ciated with a an increase in FVC (+72 ml; 95% CI +6 to
+138; p = 0.03) and an increase in TLC (+69 ml; 95%
CI +10 to +126; p = 0.02). MMP-9 manifested a border-
line association with a decline in the FEV1/FVC ratio
(-0.6%; 95% CI -1.3% to +0.01%; p = 0.053), but, in con-
trast to the general pattern, an increase in absolute
FEV1 (+14 ml; 95% CI -4 to +33; p = 0.13).
COPD Exacerbations
In each of the three 3 month periods, the number of
COPD exacerbations followed an approximately Poisson
distribution with 20% to 22% of subjects experiencing at
least 1 COPD exacerbation in each period. Over all 3
time periods, 42% of subjects experienced at least one
COPD exacerbation. An interquartile range higher level
of MMP-9 predicted an annualized average of 0.27 addi-
tional COPD exacerbations (95% CI 0.10 to 0.45; p =
0.003) (Table 4).
Secondary Analyses
As shown in Table 5, controlling additionally for hs-
CRP levels in multivariable longitudinal analyses did not
meaningfully alter the relationship between MMP-9 and
the outcomes studied. Furthermore, hs-CRP levels were
not predictive of changes in pulmonary status, except in
the case of resting oxygen saturation (p = 0.001), nor
was CRP predictive of COPD exacerbations. CRP mani-
fested a borderline association with declines in ISWT
distance (p = 0.07). In Spearman’s rank test, MMP-9
levels were not statistically associated with hs-CRP levels
at baseline (rho = 0.13; p = 0.14), 3 months (rho =
0.004; p = 0.97), or 6 months (rho = 0.01; p = 0.92).
Controlling additionally for either FEV1 or FEV1/FVC
ratio did not substantively alter the predictive relation-
ship between MMP-9 and the outcomes and various
measures of disease progression presented in Table 4,
with the possible exception of COPD exacerbations;
when controlling for FEV1,t h en u m b e ro fC O P D
exacerbations predicted by a interquartile higher level of
MMP-9 declined from 0.27 (95% CI 0.10 to 0.45;
p = 0.003) to 0.17 (95% CI -0.02 to 0.36; p = 0.08)
(Figure 3). Estimated effect sizes or levels of statistical
significance for the other outcome measures presented
in Table 4 were not substantively changed when con-
trolling additionally for FEV1 or FEV1/FVC ratio (results
not shown).
Because COPD exacerbations may be a risk factor for
subsequent COPD exacerbations and may also theoreti-
cally result in higher MMP-9 levels, we performed a
further analysis in which we controlled for prior COPD
exacerbation, in addition to potential confounders used
in the core analyses. In that analysis, MMP-9 level
retained its role as a predictor of subsequent COPD
exacerbations (0.26 additional COPD exacerbations; 95%
CI 0.09 to 0.44; p = 0.004). Results of various secondary
analyses for the outcome of COPD exacerbations are
presented in Figure 3.
Discussion
This study provides evidence that MMP-9 is a biomar-
ker that predicts COPD progression. Our insights were
facilitated by repeated longitudinal measurements of
both MMP-9 and a variety of measures of pulmonary
status. Moreover, we carried out this longitudinal analy-
sis of MMP-9 in a relatively large cohort of AATD-asso-
ciated emphysema, a well defined phenotype that offers
a particularly valuable model of COPD progression [2].
We found that higher plasma levels of MMP-9 were
associated with poorer pulmonary status at baseline and
that MMP-9 was longitudinally associated with certain
decrements in pulmonary status and worse health out-
comes. Of note, however, this was not universally the
case for all of the pulmonary status measures we stu-
died, suggesting that the role of MMP-9 is likely to be
complex and, in particular, time-dependent. Nonethe-
less, the longitudinal associations between higher levels
Table 4 MMP-9 as a longitudinal predictor of respiratory
outcomes: lung function, lung density, functional status,
and COPD exacerbations
Outcome Measures Annualized Δ (95%
CI)*
P-
value
Spirometry
FEV1, ml +14 (-4 to +33) 0.13
FVC, ml +72 (+6 to +138) 0.03
FEV1/FVC ratio -0.6% (-1.3% to -0.1%) 0.053
Total Lung Capacity, ml +69 (+10 to +126) 0.02
Transfer Factor (TLco), mmol/min/kpa -0.1 (-0.2 to -0.004) 0.04
CT Densitometry
Adjusted Lung Density
† -0.6 (-1.1 to -0.2) 0.003
Resting Oxygenation Saturation (room
air)
-0.5% (-0.7% to -0.3%) <0.001
Incremental Shuttle Walk Test Distance
Distance Walked, meters -6 (-15 to +2) 0.16
Acute Exacerbations of COPD, number +0.27 (+0.10 to +0.45) 0.003
All analyses controlled for age, gender, race-ethnicity, leukocyte count, and
tobacco pack-year history. Analysis of total lung capacity also controlled for
method of lung capacity assessment (box plethysmography vs helium
dilution).
*Annualized longitudinal change (Δ) predicted by a 25
th -7 5
th percentile
interquartile range higher level of MMP-9.
†Measured in Hounsfield Units at the 15
th percentile.
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both findings that support higher MMP-9 levels being a
marker for pulmonary parenchymal destruction. Thus,
our longitudinal findings with respect to lung density
and TLco suggest that, in AATD-associated emphysema,
further study of a direct involvement of MMP-9 in dis-
ease progression is warranted.
The magnitude of the prospective associations
between MMP-9 and pulmonary status measurements
was, in many cases, modest from a clinical perspective,
but the time period examined was short relative to the
multi-year timeframe over which emphysema progresses.
Indeed, the longitudinal changes observed in the various
pulmonary status measures, irrespective of MMP-9
levels, were themselves small. That many findings asso-
ciated with MMP-9 were statistically significant, despite
the relatively short period of follow-up, is thus all the
more noteworthy.
Although MMP-9 was cross-sectionally associated
with lower FEV1, its longitudinal association with
obstructive ventilatory defects was ambiguous, with
higher MMP-9 levels being associated prospectively with
a lower FEV1/FVC while associated with a higher FEV1,
Table 5 Secondary Analysis: The addition of hs-CRP into longitudinal models of respiratory outcomes did not
substantively change the predictive relationship between MMP-9 and the outcomes examined
Outcome Measures MMP-9
Annualized Δ*
(95% CI)
p-value
hs-CRP
Annualized Δ*
(95% CI)
p-value
Spirometry
FEV1, ml +15 (-4 to +34)
p = 0.12
-25 (-73 to +22)
p = 0.29
FVC, ml +72 (+6 to +139)
p = 0.03
-28 (-192 to +136)
p = 0.73
FEV1/FVC ratio -0.6%(-1.3% to +0.01%)
p = 0.053
-1.3%(-2.9% to +0.3%)
p = 0.11
Total Lung Capacity, ml +69 (+10 to +127)
p = 0.02
+17 (-156 to +190)
p = 0.85
Transfer Factor (TLco), mmol/min/kpa -0.1 (-0.2 to -0.002)
p = 0.047
-0.07 (-0.4 to -0.2)
p = 0.63
CT Densitometry
Adjusted Lung Density
† -0.6 (-1.0 to -0.2)
p = 0.006
+0.7 (-0.3 to +1.7)
p = 0.16
Resting Oxygenation Saturation (room air) -0.4%(-0.6% to -0.2%)
p < 0.001
-0.9% (-1.4 to -0.4)
p = 0.001
Incremental Shuttle Walk Test Distance, meters -6 (-14 to +3)
p = 0.20
-20 (-42 to +1)
p = 0.07
Acute Exacerbations of COPD, number +0.26 (+0.08 to +0.45)
p = 0.006
+0.16 (-0.6 to +0.9)
p = 0.67
All analyses included age, gender, race-ethnicity, leukocyte count, tobacco pack-year history, MMP-9 levels, and hs-CRP levels as independent variables in a
multivariable model. Analysis of total lung capacity also controlled for method of lung capacity assessment (box plethysmography vs helium dilution).
*Annualized longitudinal change (Δ) predicted by a 25-75
th interquartile range higher level of MMP-9 or hs-CRP, respectively.
†Measured in Hounsfield Units at the 15
th percentile.
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Figure 3 Primary and secondary analyses of incremental
annual acute exacerbations of COPD (AECOPDs) predicted per
interquartile higher level of MMP-9. The primary analysis controls
for age, gender, race-ethnicity, leukocyte count, and tobacco pack-
years. Secondary analyses control for the same covariates as those
used in primary analyses and one of the following: hs-CRP, FEV1,
FEV1/FVC, or COPD exacerbation in the prior period.
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Research on MMP-9’s association with airway pathology
is limited [14], but this finding does stand in contrast to
that of Hashimoto and colleagues [8]. On the other
hand, Vignola and colleagues, in their cross-sectional
study, also found a positive correlation between MMP-9
and higher FEV1 [48]. One theoretical explanation for a
paradoxical association with decreased FEV1/FVC ratio
but increased FEV1 would be that destruction of pul-
monary parenchyma, and its associated airway tethering,
may potentially result in greater reductions in longitudi-
nal than radial airway traction and thus work to increase
small airway caliber [49]. It is also possible that this
finding was simply a chance observation, especially
given that the longitudinal association with increased
FEV1 did not meet criteria for statistical significance.
Moreover, the annualized decline in FEV1 of 36 ml in
this cohort is substantially lower than the 54 ml annual
decline that has previously been observed in AATD-
associated emphysema [50]. This finding magnifies the
inherent limitations of studying FEV1,a ne n d p o i n tt h a t
can be problem-ridden in airways disease because of its
variability and effort dependence. Indeed, this was part
of the impetus for choosing lung density, rather than
FEV1, as the primary outcome in the REPAIR trial [19].
The fact that the longitudinal associations observed
with respect to MMP-9 persisted even after controlling
for both leukocyte count and hs-CRP levels argues that
these predictive observations are not merely reflective of
MMP-9 as a non-specific inflammatory marker. Indeed,
MMP-9 was poorly correlated with hs-CRP levels.
Further, hs-CRP was itself a relatively poor predictor of
changes in pulmonary status and did not predict COPD
exacerbations. CRP has shown some variable ability to
predict COPD progression and outcomes, although this
has generally been examined in non-AATD cohorts
which included active smokers, who were excluded here
[46,47,51]. Thus, the positive associations found with
respect to MMP-9 are more remarkable in the context
of an absence of consistently positive findings associated
with CRP levels.
Our study was not designed to establish a causative
role of MMP-9 in antitrypsin deficient emphysema pro-
gression. Evidence from other studies suggest that
MMP-9 degrades basement membrane type IV collagen,
insoluble elastin, and other matrix proteins important to
the function and structural integrity of the lung par-
enchyma [14-16]. MMP-9 has also been shown, through
amino terminal processing, to potentiate interleukin-8
chemotactic activity for neutrophils ten-fold, providing
an additional inflammatory pathway for lung damage
and COPD exacerbations [18]. Nonetheless, we cannot
exclude the possibility that our observations could be
attributable to a confounding correlation between
MMP-9 and other factors that contribute to COPD
exacerbations or the progression of emphysema. For
example, MMP-9 is released primarily by neutrophils
and macrophages; these leukocytes could by themselves
be responsible for some of our observations, indepen-
dent of MMP-9. Our analysis controlled for leukocyte
count, and the presumed primary mechanism of action
for MMP-9 is biologically coherent in playing a causa-
tive role in some of the effects we observed, but this
s t u d ys u p p o r t so n l yt h ec o n c l u s i o nt h a tM M P - 9i sa
biomarker that predicts disease progression but not
necessarily that MMP-9 plays an etiologic role.
There are additional limitations of our research
beyond those alluded to above. Despite the advantages
in studying AATD-associated emphysema, our findings
may not be generalizable to COPD in the absence of
AATD and, indeed, the AATD registry from which
patients were recruited for this study represents only a
subset of AATD. Further, this study was also conducted
in subjects who had been non-smokers for at least
6 months, and it is unclear whether current tobacco
smoking might alter the relationship between MMP-9
and pulmonary outcomes. The assay used to quantify
MMP-9 measured total MMP-9 concentration rather
than MMP-9 enzymatic activity as measured by bioas-
say. While measurement of enzymatic activity may have
been preferable in providing greater ability to find asso-
ciations [52], reduced accuracy from relying on total
MMP-9 would tend to diminish our ability to demon-
strate statistically significant associations, but does not
argue against the validity of associations that we did
observe. Finally, assessments of MMP-9 and pulmonary
status and outcomes were not performed on an ideal
schedule and frequency. For instance, some measure-
ments, such as PFTs, were available every 3 months
while others, such as lung density, were available every
6 months. The lack of an MMP-9 measurement at
9 months also places constraints on our analysis. In the
best of all possible worlds, an MMP-9 assessment far
more frequently than every 3 months (e.g., every two
weeks) might have provided data clarifying MMP-9 fluc-
tuations in relation to disease outcomes, in particular
COPD exacerbations. Nonetheless, the repeated longitu-
dinal measurements in this study, although imperfect,
are a key strength of the analysis.
Conclusions
Among patients with AATD-associated emphysema, our
data show that higher plasma MMP-9 levels were gener-
ally associated, both cross-sectionally and longitudinally,
with poorer and declining pulmonary status, across
multiple endpoints. Overall, this study supports prior
Omachi et al. Respiratory Research 2011, 12:35
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Page 9 of 11research indicating MMP-9 may be a valuable biomarker
for the progression of emphysema.
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